Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa by Cillóniz, Catia et al.
Accepted Manuscript
Community-Acquired Pneumonia due to Multidrug and non-Multidrug resistant
Pseudomonas aeruginosa
Catia Cillóniz, PhD, Albert Gabarrús, MSc, Miquel Ferrer, MD, Jorge Puig de la
Bellacasa, MD, Mariano Rinaudo, Josep Mensa, MD, Michael S. Niederman, MD,
Antoni Torres, MD
PII: S0012-3692(16)47572-0
DOI: 10.1016/j.chest.2016.03.042
Reference: CHEST 408
To appear in: CHEST
Received Date: 15 January 2016
Revised Date: 22 March 2016
Accepted Date: 25 March 2016
Please cite this article as: Cillóniz C, Gabarrús A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J,
Niederman MS, Torres A, Community-Acquired Pneumonia due to Multidrug and non-Multidrug resistant
Pseudomonas aeruginosa, CHEST (2016), doi: 10.1016/j.chest.2016.03.042.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Community-Acquired Pneumonia due to Multidrug and non-Multidrug 
resistant Pseudomonas aeruginosa  
Catia Cillóniz, PhD
1
; Albert Gabarrús, MSc
1
; Miquel Ferrer, MD
1
; Jorge Puig de la 
Bellacasa, MD
2
; Mariano Rinaudo
1
; Josep Mensa, MD
3
; Michael S. Niederman, MD
4
; 
Antoni Torres, MD
1 
 
1 
Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona - 
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of 
Barcelona (UB) - SGR 911- Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, 
Spain. 
2 
Department of Microbiology, Hospital Clinic, Barcelona, Spain. 
3 
Department of Infectious Disease, Hospital Clinic, Barcelona, Spain 
4
 Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College  
Running Head: Pseudomonas aeruginosa CAP 
Word count of the body of the manuscript: 2,930 
 
Funding: The study was funded by Ciber de Enfermedades Respiratorias (CibeRes 
CB06/06/0028). 2009 Support to Research Groups of Catalonia 911. 
 
Conflicts of interest: We declare no conflicts of interest. 
Corresponding author: 
Antoni Torres, MD 
Department of Pneumology, Hospital Clinic of Barcelona, Spain 
c/ Villarroel 170, 08036 Barcelona, Spain 
Email: atorres@clinic.ub.es 
Abbreviations list 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Community-acquired pneumonia (CAP) 
Multidrug-resistant (MDR) 
(AIDS) 
Extensively drug-resistant (XDR) 
Pandrug-resistant (PDR) 
Tracheobronchial aspirates (TBAS) 
Bronchoalveolar lavage (BAL) 
Polymerase chain reaction (PCR) 
Pneumonia Severe Index (PSI) 
Consciousness, Urea, Respiratory rate, Blood pressure, 65 years old (CURB-65) 
Confidence intervals (CIs) 
Receiver operating characteristic (ROC) 
Mean (SD) 
Interquartile range (IQR) 
Chronic obstructive pulmonary disease (COPD) 
Intensive Care Unit (ICU) 
Length of stay (LOS) 
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ABSTRACT  
Background: Pseudomonas aeruginosa is not a frequent pathogen in Community 
Acquired Pneumonia (CAP). However, in patients with severe CAP, P. aeruginosa can 
be the etiology in 1.8% to 8.3% of patients, with a case-fatality rate of 50% to 100%. 
We describe the prevalence, clinical characteristics, outcomes and risk factors 
associated with CAP due to multidrug and non-multidrug resistant P. aeruginosa.  
Methods: Prospective observational study of 2023 consecutive adult CAP patients with 
definitive etiology. 
Results: P. aeruginosa was found in 77 (4%) of the 2023 cases with microbial etiology. 
In 22 (32%) of the 68 cases of P. aeruginosa with antibiogram data, the isolates were 
multidrug-resistant (MDR). Inappropriate therapy was present in 49 (64%) cases of P. 
aeruginosa CAP, including 17/22 (77%) cases of MDR P. aeruginosa CAP. Male sex, 
chronic respiratory disease, C-reactive protein <12.35 mg/dL, and PSI risk class IV – V 
were independently associated with P. aeruginosa CAP. Prior antibiotic treatment was 
more frequent in MDR P. aeruginosa CAP compared with non-MDR P. aeruginosa (58% 
vs. 29%, p=0.029), and was the only risk factor associated with CAP due to MDR P. 
aeruginosa. In the multivariate analysis, age ≥65 years, CAP due to P. aeruginosa, 
chronic liver disease, neurologic disease, nursing-home, criteria of ARDS, acute renal 
failure, ICU admission, and inappropriate empiric treatment were the factors 
associated with 30-day mortality.  
Conclusions: P. aeruginosa is an individual risk factor associated with mortality in CAP. 
The risk factors described can help clinicians to suspect P. aeruginosa and MDR P. 
aeruginosa. 
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INTRODUCTION 
Pseudomonas aeruginosa is not a frequent pathogen in community-acquired 
pneumonia (CAP)
1-4
. Several studies have reported that P. aeruginosa was the cause in 
1.8% to 8.3% of patients with severe CAP requiring intensive care unit (ICU) admission, 
with a case-fatality rate of 50% to 100%
5-9
. Since antibiotic treatment for P. aeruginosa 
is completely different from the standard treatment to cover common pathogens in 
CAP (Streptococcus pneumoniae, Legionella pneumophila, and atypical bacteria), 
current guidelines for severe CAP stratify therapy recommendations on the basis of 
Pseudomonal risk factors. However, since those guidelines were published, highly 
resistant forms of this pathogen have emerged, and for these patients, treatment is 
even more difficult. Many years ago, our group published a study
10
 on P. aeruginosa in 
CAP. In that study, the prevalence of P. aeruginosa was 6.9% and mortality was 28%. 
Currently, the prevalence of multidrug-resistant (MDR) P. aeruginosa is well known in 
nosocomial pneumonia, but its prevalence in CAP is not well described, and this is now 
an important organism because of its potential impact on empiric-therapy choices. 
Knowledge of the associated risk factors for both MDR and non-MDR P. aeruginosa 
could prompt early recognition and diagnosis, and adequate initial antimicrobial 
therapy, considering the increasingly common population of patients with MDR 
Pseudomonal CAP. 
Therefore, we have studied the prevalence, risk factors, and outcomes for P. 
aeruginosa in a non-immunosuppressed population with CAP. We also investigated the 
rates, risk factors, and outcomes of MDR P. aeruginosa. 
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METHODS  
Study Design and Patients 
We performed an observational cohort study of consecutive patients admitted to 
Hospital Clinic, Barcelona, Spain, between January 1999 and December 2014 with a 
diagnosis of community-acquired pneumonia. The exclusion criteria were: a) patients 
without a positive microbiologic diagnosis, b) severe immunosuppression (AIDS, 
chemotherapy, immunosuppressive drugs [e.g., oral corticosteroid ≥10 mg prednisone 
or equivalent per day for at least two weeks]), c) health care-associated pneumonia 
cases, d) active tuberculosis, e) patients with cystic fibrosis, and f) cases with a 
confirmed alternate diagnosis (additional details are shown in e-Methods in 
Supplementary Data). We include nursing home patients for the following reasons: 1-
In Spain, the definition of nursing-home is very heterogeneous and it is unclear if all 
these would belong to an HCAP group. 2- In a previous article published by our group 
in Thorax (Polverino et al
11
) on nursing-home patients, we observed that microbial 
etiology was not very different compared to CAP. The study was approved by the 
Ethics Committee of our institution (Register: 2009/5451). Written informed consent 
was waived due to the non-interventional design. 
Data Collection  
The following parameters were recorded at admission: age, sex, current 
smoking, alcohol habits and drug consumption, co-morbidities, antibiotic treatment in 
the 30 days prior to hospital admission, treatment with corticosteroids (<10 mg 
prednisone or equivalent and inhaled corticosteroids), clinical symptoms and features, 
clinical signs, arterial blood gas measurements, chest radiograph findings, laboratory 
parameters, diagnostic procedures, empiric antibiotic therapy, ventilator support, 
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pulmonary complications, and other clinical events. The duration of treatment, length 
of hospital stay, and 30-day in-hospital mortality were recorded. We also calculated 
the pneumonia severity index (PSI) and CURB-65 score
12;13
 at admission. 
Definitions 
Pneumonia was defined as a new pulmonary infiltrate found on the hospital 
admission chest x-ray, with symptoms and signs of lower respiratory tract infection 
(e.g., fever, cough, sputum production, pleuritic chest pain) in persons who have not 
been hospitalized recently and have not had regular exposure to the health care 
system. 
P. aeruginosa pneumonia was defined as pneumonia where P. aeruginosa was 
isolated in blood or in a valid respiratory sample (see Supplementary data).  
 Prior antibiotic treatment was considered when antibiotics had been taken in 
the previous month. Appropriateness of empiric antibiotic treatment in all patients 
was defined according to multidisciplinary guidelines for the management of 
community acquired pneumonia
14
. Appropriateness of empiric antimicrobial 
treatment in patients was defined when the isolated pathogens were susceptible in 
vitro to ≥1 of the antimicrobials administered, except in the case of P. aeruginosa. For 
P. aeruginosa infection, initial appropriate empiric treatment required two antibiotics 
active against the isolated strain 
15
.  
Resistance of P. aeruginosa to multiple antibiotics was defined as Multi-drug 
resistant (MDR), extensively drug-resistant (XDR) or pandrug-resistant (PDR), as 
described else where
16
. 
Polymicrobial pneumonia was defined when more than one pathogen was 
identified as the causative agent 
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Severe CAP was defined when at least one major or 3 minor criteria of the 
Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines 
were present
17
. Chronic respiratory disease was defined as treatment for asthma, 
simple chronic bronchitis or chronic obstructive disease (COPD defined as a 
documented irreversible airflow obstruction); bronchiectasis or the presence of 
interstitial lung disorders. 
Microbiological Evaluation 
Microbiologic examination was performed on sputum, urine, two samples of 
blood and nasopharyngeal swabs. Pleural fluid, tracheobronchial aspirates (TBAS) and 
bronchoalveolar lavage (BAL) fluid, when available, were collected for Gram and Ziehl-
Nielsen stains and for cultures for bacterial, fungal and mycobacterial pathogens. 
Sputum (see supplementary data) and blood samples were obtained for 
bacterial culture before the start of antibiotic therapy in the emergency department. 
Nasopharyngeal swab for respiratory virus detection was collected when available; 
urine samples for Streptococcus pneumoniae and Legionella pneumophila antigen 
detection were obtained within 24 hours after hospital admission. Blood samples for 
serology of atypical pathogens and respiratory virus were collected at admission and 
between the third and sixth week thereafter. 
Routine antimicrobial susceptibility testing included the Phoenix system 
(Becton Dickinson, MD, USA) for P. aeruginosa isolated from blood cultures and the 
disk diffusion method or E-test for P. aeruginosa isolated from respiratory samples. 
Results of susceptibility testing were interpreted according to EUCAST guidelines
18
. 
Statistical Analysis 
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 We report the number of patients (%) for categorical variables, the median (1st 
quartile; 3rd quartile) for continuous variables with non-normal distribution, and the 
mean (SD) for those with normal distribution. Categorical variables were compared 
using the χ
2
 test or the Fisher exact test. Continuous variables were compared using 
the t test or the nonparametric Mann-Whitney test. Univariate and multivariate 
logistic regression analyses were performed to identify variables associated with the 
presence of CAP due to P. aeruginosa (see supplementary data for the full list of 
variables); we performed a subgroup analysis for patients with chronic respiratory 
disease. 
Also univariate and multivariate logistic regression analyses were performed to 
identify variables associated with MDR in patients with P. aeruginosa. Variables that 
showed a significant result in the univariate analysis (p<0.1) were included in the 
corresponding multivariate logistic regression backward stepwise model. Strongly 
correlated variables were excluded from multivariate analyses. The association with 
30-day mortality was also tested by means of univariate and multivariate analysis, and 
similar inclusion criteria were applied for the logistic regression analysis (p<0.1); we 
performed a subgroup analysis for patients with P. aeruginosa. The Hosmer-Lemeshow 
goodness-of-fit test was performed to assess the overall fit of the model
19
. Internal 
validation of the prediction models was conducted using ordinary nonparametric 
bootstrapping with 1000 bootstrap samples and bias-corrected, accelerated 95% 
confidence intervals (CIs). Receiver operating characteristic (ROC) curves were 
constructed for the ability to predict patients with CAP due to P. aeruginosa, patients 
with CAP due to MDR P. aeruginosa, and 30-day mortality, using significant variables 
derived from the respective logistic regression model. All tests were 2-tailed and 
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significance was set at 0.05. All analyses were performed with IBM SPSS Statistics 
version 20.0 (Armonk, New York, USA). 
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RESULTS 
Patient Characteristics 
A total of 5384 consecutive patients with CAP were enrolled during the study 
period. The final study population consisted of 2023 patients with an established 
microbial etiology (Figure 1). There were 1253 (62%) males and the mean (SD) age was 
65 (19) years. CAP was due to P. aeruginosa in 77 of 2023 cases (4%). Sixty-eight cases 
of the 77 (88%) had susceptibility data, and 22 (32%) were multidrug resistant (MDR) 
P. aeruginosa and 46 (68%) were non MDR P. aeruginosa. We did not find XDR or PDR 
strains of P. aeruginosa.  
On average, patients with CAP due to P. aeruginosa were older and more 
frequently males, received prior antibiotics and inhaled corticosteroids more often, 
had a higher proportion of chronic respiratory disease, especially chronic obstructive 
pulmonary disease (COPD), and were more likely to have a history of a previous 
episode of pneumonia, compared to those with other pathogens (Table 1). They also 
had a more severe clinical presentation (respiratory rate, respiratory failure) at 
admission, but less fever, less pleuritic pain and lower levels of C-reactive protein. A 
total of 23% were admitted to the ICU, which is not significantly higher than in other 
CAP patients. A higher percentage of patients with CAP due to P. aeruginosa was in PSI 
risk class IV-V and CURB-65 class 3-5 than patients with CAP caused by other 
pathogens. The 30-day mortality rate was significantly higher in patients with CAP due 
to P. aeruginosa (18 % vs. 6%, p<0.001).  
The differences in baseline characteristics between MDR and non-MDR P. 
aeruginosa CAP are summarized in Table 2. MDR P. aeruginosa CAP patients had 
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received prior antibiotics significantly more often (58% vs. 29%, p=0.029) and the rate 
of pneumonia in the previous year was also higher (46% vs. 21%, p=0.034).  
Microbiology 
In the group of patients with CAP caused by other pathogens, the five most 
frequent pathogens were Streptococcus pneumoniae (862 [44%]), respiratory viruses 
(302 [16%]), polymicrobial etiology (238 [12%]), Legionella pneumophila (121 [6%]) and 
other atypical bacteria (143 [7%]). P. aeruginosa was the eighth most common 
pathogen overall (e-Table 1).  
Susceptibility testing was performed in 68 of the 77 P. aeruginosa isolates 
(88%). Thirty-two isolates (47%) showed in-vitro resistance to ciprofloxacin, 15 (24%) 
were resistant to piperacillin–tazobactam, 16 (24%) to gentamicin, 14 (24%) to 
tobramycin, 15 (22%) to ceftazidime, 15 (22%) to imipenem, 15 (22%) to meropenem, 
7 (11%) to colistin, and 2 (3%) to amikacin. Twenty-two strains (32%) were classified as 
MDR P. aeruginosa.  
Antibiotic Treatment  
 Data on antibiotic treatment was available in 1965 patients (97%). In general, 
the most frequent regimens were a combination of a cephalosporin plus a macrolide 
(700 [36%]), fluoroquinolone monotherapy (417 [21%]), cephalosporin plus 
fluoroquinolone (392 [20%]), ß-lactam-ß-lactamase inhibitor plus fluoroquinolone (56 
[3%]), and cephalosporin monotherapy (54 [3%]). 
Compared to other CAP patients, the group with CAP due to P. aeruginosa 
received more often cephalosporin monotherapy (5 [7%] vs. 49 [3%], p=0.024), and 
cephalosporin plus aminoglycosides (8 [11%] vs. 18 [1%], p<0.001), and less frequently 
fluoroquinolone monotherapy (7 [10%] vs. 410 [22%], p=0.017). No significant 
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differences in empiric antibiotic regimens were found between those with MDR and 
with non-MDR P. aeruginosa pneumonia. 
The empiric antimicrobial treatment was inadequate in 206 of all cases (13%). 
In the group with CAP due to P. aeruginosa, 49 cases (64%) had inadequate empiric 
antimicrobial treatment (3 cases were inadequate because only one correct antibiotic 
was used) compared to the 157 cases (10%) in the group with CAP due to other 
pathogens (p<0.001). Seventeen of the 22 MDR cases (77%) were treated inadequately 
compared to the 28 of the 46 non-MDR cases (61%) (p=0.18). 
Outcomes 
Severe CAP was significantly more frequent in the group of CAP due to P. 
aeruginosa (62% vs. 28%, p<0.001) compared with the group of other pathogens, but 
use of the ICU was similar in both groups. Thirty-day mortality was significantly higher 
for patients with CAP due to P. aeruginosa, compared with the group of other 
pathogens (18% vs. 6%, p<0.001). Length of hospital stay was longer in CAP due to P. 
aeruginosa compared with CAP due to other microorganisms (7 [5; 12] vs. 13 [7; 16.5] 
days, p<0.001) (Table 1). Also, there was a longer median length of hospital stay of the 
MDR group compared with non-MDR P. aeruginosa CAP (14 [12; 21] vs. 11 [7; 16] days, 
p=0.046) (Table 2). 
Clinical Factors Associated With CAP Due to P. aeruginosa 
Several variables were significantly associated with CAP due to P. aeruginosa in 
the univariate logistic regression analyses (Table 3). Of these variables, male sex, 
chronic respiratory disease, C-reactive protein lower than 12.35 mg/dL, and PSI risk 
class IV-V were risk factors in the multivariate analysis. Internal validation of the 
logistic regression model was conducted using bootstrapping with 1000 samples (e-
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Table 2). The four variables included in the model demonstrated robust results, with 
small 95% CIs around the original coefficients. The area under the ROC curve was 0.74 
(95% CI 0.68-0.79) for the model predictive of CAP due to P. aeruginosa. 
In the subgroup of patients with chronic respiratory disease, previous treatment with 
inhaled corticosteroids was the only variable associated with CAP due to P. aeruginosa 
in the multivariate analysis (e-Table 3). The area under the ROC curve was 0.62 (95% CI 
0.52-0.71). 
Associations of CAP Due to MDR P. aeruginosa 
In the subgroup of CAP due to P. aeruginosa patients, the only risk factor 
associated with CAP due to MDR P. aeruginosa in the multivariate analysis was prior 
antibiotic treatment (Table 4). The area under the ROC curve was 0.64 (95% CI 0.49-
0.80). 
Predictors of 30-Day Mortality 
 In the multivariate logistic regression analysis, the following factors were 
independently associated with 30-day mortality: CAP due to P. aeruginosa, age ≥65 
years, chronic liver disease, neurologic disease, nursing home, acute renal failure, ICU 
admission, and inappropriate initial empiric treatment (Table 5). The area under the 
ROC curve was 0.86 (95% CI 0.82-0.90) for the model predictive of 30-day mortality. 
 
In the subgroup of CAP due to P. aeruginosa patients, previous treatment with 
inhaled corticosteroids and acute renal failure were the variables associated with 30-
day mortality in the multivariate analysis (e-Table 4). The area under the ROC curve 
was 0.83 (95% CI 0.72-0.95). 
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DISCUSSION 
The main findings of this study are the following: 1.-The prevalence of CAP due 
to P. aeruginosa in this large series of consecutive patients with CAP was 4% of 
patients with a defined etiology, and 32% of these patients had MDR P. aeruginosa. 2.-
We identified several risk factors associated with CAP due to P. aeruginosa in general 
and for CAP due to MRD P. aeruginosa. 3.-CAP due to P. aeruginosa was associated 
with a significantly higher rate of inappropriate therapy than CAP due to other 
pathogens (65% vs. 11%; p<0.001). 4.-CAP due to P. aeruginosa was associated with 
CAP mortality in a multivariate model.  
 The prevalence of 4% found in our study is higher than other studies, but this 
was only for patients with an established etiology and for the entire population, the 
frequency was 1.2%. In another report from Spain,
20
 the prevalence was 1.5% in 
patients with microbial etiology. In  a large retrospective study from San Antonio,
21
 the 
prevalence of P. aeruginosa was 1.1%. 
If we compare the current results with the article from our group published 
more than 10 years earlier, corresponding to the 1997-1998 period, the prevalence of 
P. aeruginosa CAP was 6.9%
4
. From these figures, it is clear that, at least in our 
institution, the burden of P. aeruginosa in CAP has decreased. An explanation for these 
differences is the much better ambulatory care, less indiscriminate use of antibiotics, 
and prevention of pneumonia in the two populations at major risk: COPD and 
bronchiectasis patients. Furthermore, if we compare current 30-day mortality (18%) 
with prior data (28%), we can see that 30-day mortality in CAP caused by P. aeruginosa 
has decreased, reflecting changes in management. For the first time in the literature 
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we provide data and differential characteristics regarding MDR versus non-MDR 
Pseudomonas aeruginosa 
Only two studies have investigated risk factors for P. aeruginosa CAP in 
multivariate analyses. We identified four risk factors in the multivariate analysis. In our 
previous study in 2002,
22
 we did not perform a multivariate analysis but we found that 
P. aeruginosa was associated with male sex, previous hospital admission, pulmonary 
comorbidity and ICU admission. From all this information, it appears that the key 
factor is chronic respiratory disease. In the absence of chronic respiratory disease, 
there is probably no need for empiric therapy to cover P. aeruginosa in 
immunocompetent patients.  
In addition, we performed a multivariable analysis to determinate risk factors 
for P. aeruginosa in the population with chronic respiratory conditions and found that 
the use of inhaled corticosteroids was the only risk factor for P. aeruginosa pneumonia 
in this population. Overall, inhaled corticosteroids are a well-defined risk factor for CAP 
and possibly for a specific pathogen such as P. aeruginosa. 
An important finding of our study is that that P. aeruginosa was MDR in 32% of 
the isolates with antibiogram data. This has not been previously reported and the only 
risk factor associated with P. aeruginosa MDR was previous antibiotic treatment. A 
clinical consequence of this finding is to use antibiotics covering MDR Pseudomonas 
when P. aeruginosa is suspected and there is prior antibiotic treatment. 
The raw mortality of P. aeruginosa CAP was 18% in our series, similar to a 
recent manuscript published in Respirology
23
. P. aeruginosa was an independent factor 
associated with mortality even after adjustment for inadequate antibiotic treatment. 
In the subpopulation of MDR P. aeruginosa, P. aeruginosa was not a factor associated 
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with mortality, suggesting that these resistant strains, although more difficult to treat, 
may be  less virulent
24;25
. Previous inhaled corticosteroids were independently 
associated with higher mortality (OR, 12.80) in this subpopulation, which contrasts 
with previous reports that found inhaled corticosteroids to be protective for 
complications and mortality
26;27
.  
We published in 1991 a manuscript in which we observed that Pseudomonas 
was associated with higher independently mortality. However, that series included 
only 5 cases of Pseudomonas CAP which makes very difficult to compare with the 
presented study in which we included 77 cases 
5
. 
Our study has 2 major limitations. First, it is a single-center study in a teaching 
hospital covering a population of more than half a million persons. This may not apply 
to other hospitals with different populations. Second, this was a 12-year study, but the 
standards for diagnosing P. aeruginosa CAP have not varied during that period. The 
major strengths of the study are that it is a very large series of CAP patients and that 
we studied the resistance patterns of most of the P. aeruginosa isolates and found 
data that may be helpful in guiding empiric therapy of CAP in the current era of drug-
resistant P. aeruginosa. 
Conclusions 
In summary, we found that, while not common, Pseudomonas aeruginosa was 
a cause of CAP and one that is often treated inappropriately (64% of patients). Some 
32% of cases are have multidrug resistant, and these patients need to be identified 
because we found that 77% received inappropriate empiric therapy. Compared to 
other forms of CAP, patients with P. aeruginosa had severe disease more commonly 
(62% vs. 28%). In this series, as in others, inappropriate empiric antibiotic therapy was 
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a mortality risk for all patients with CAP, so identification of patients requiring special 
therapy, such as those with P. aeruginosa, is essential to assure correct therapy 
choices. Those most at risk for P. aeruginosa were patients with chronic respiratory 
disease, particularly those receiving inhaled corticosteroids, although patients 
receiving high dose systemic corticosteroids were excluded from this analysis. 
Although this organism is uncommon, awareness of it is important because the 
presence of P. aeruginosa was an independent predictor for mortality among patients 
with CAP.  
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Figures Legend 
 
Figure 1: Flow diagram of the selected population 
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Table 1. Clinical and Epidemiological Characteristics of CAP and CAP Caused by P. 
aeruginosa 
 
Other Pathogens 
(n = 1,946) 
P. aeruginosa 
(n = 77) P Value 
Demographic    
    Age (years), mean (SD) 65.2 (18.8) 71.4 (14.6) 0.008 
    Male gender, No. (%) 1,187 (61.3) 65 (84.4) <0.001 
    Current smoker, No. (%) 549 (28.4) 16 (21.9) 0.22 
    Current alcohol consumer, No. (%) 307 (15.9) 17 (23.3) 0.094 
Previous antibiotic, No. (%) 400 (21.5) 24 (34.3) 0.012 
Influenza vaccine, No. (%) 630 (39.7) 26 (45.6) 0.37 
Pneumococcal vaccine, No. (%) 247 (15.6) 12 (21.1) 0.27 
Inhaled corticosteroid, No. (%) 360 (18.8) 33 (44.6) <0.001 
Systemic corticosteroid, No. (%) 88 (5.0) 3 (4.9) 0.97 
Comorbidities, No. (%)* 1,251 (64.3) 64 (83.1) 0.001 
    Chronic respiratory disease 826 (43.3) 51 (68.0) <0.001 
        Chronic bronchitis 165 (8.7) 4 (5.3) 0.31 
        Bronchiectasis 55 (2.9) 5 (6.7) 0.061 
        COPD 341 (17.9) 29 (38.7) <0.001 
         Asthma 94 (4.9) 2 (2.7) 0.37 
        Other 171 (9.0) 11 (14.7) 0.094 
    Chronic cardiovascular disease 255 (13.2) 13 (17.3) 0.31 
    Diabetes mellitus 350 (18.2) 14 (18.7) 0.93 
    Neurological disease 283 (15.0) 15 (20.5) 0.19 
    Chronic renal disease 116 (6.0) 7 (9.3) 0.24 
    Chronic liver disease 96 (5.0) 5 (6.6) 0.54 
Previous episode of pneumonia, No. (%) 268 (14.3) 21 (28.0) 0.001 
Nursing-home, No. (%) 103 (5.4) 5 (6.7) 0.62 
Clinical findings    
     Cough, No. (%) 1,551 (81.0) 61 (81.3) 0.95 
     Purulent sputum, No. (%) 1,145 (61.2) 52 (72.2) 0.060 
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Other Pathogens 
(n = 1,946) 
P. aeruginosa 
(n = 77) P Value 
     Dyspnea, No. (%) 1,308 (68.7) 59 (78.7) 0.067 
     Pleuritic pain, No. (%) 808 (42.6) 21 (27.6) 0.010 
     Fever, No. (%) 1,618 (84.3) 56 (73.7) 0.013 
     Altered mental status, No. (%) 332 (17.2) 19 (25.3) 0.069 
     Respiratory rate (breaths/min), median (1st 
quartile; 3rd quartile) 
24 (20; 32) 28 (24; 32) 0.005 
     Respiratory rate ≥30 breaths/min, No. (%) 553 (31.4) 31 (44.9) 0.018 
     Heart rate (beats/min), median (1st 
quartile; 3rd quartile) 
100 (86; 112) 100 (80; 112) 0.58 
     Heart rate ≥100 beats/min, No. (%) 958 (51.5) 38 (52.1) 0.93 
Laboratory findings    
     Creatinine (md/dL), median (1st quartile; 
3rd quartile) 
1.1 (0.9; 1.5) 1.1 (0.8; 1.6) 0.90 
     Creatinine ≥1.5 md/dL, No. (%) 473 (24.6) 23 (30.3) 0.27 
     C-reactive protein (mg/dL), median (1st 
quartile; 3rd quartile) 
20.4 (10.4; 29.3) 15.6 (7.7; 26.2) 0.033 
     C-reactive protein ≥12.35 mg/dL, No. (%)# 1,081 (70.2) 32 (54.2) 0.009 
     White blood cell count (× 109/L), median 
(1st quartile; 3rd quartile) 
13.1 (8.8; 18.3) 14.2 (9.8; 20.6) 0.28 
     White blood cell count ≥10 × 109/L, No. (%) 1,314 (68.7) 56 (74.7) 0.28 
     PaO2/FIO2 ratio, median (1st quartile; 3rd 
quartile) 
281 (238; 324) 255 (203; 291) 0.002 
     PaO2/FIO2 ratio <250, No. (%) 444 (31.6) 29 (49.2) 0.005 
CURB-65 risk class 3-5, No. (%) 344 (18.7) 24 (32.9) 0.003 
PSI risk class IV-V, No. (%) 977 (50.5) 54 (72.0) <0.001 
ICU admission, No. (%) 378 (19.4) 18 (23.4) 0.38 
Mechanical ventilation, No (%)$   0.17 
    Not ventilated 1,517 (89.4) 52 (89.7) 0.96 
    Non-invasive 68 (4.5) 0 (0) 0.12 
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Other Pathogens 
(n = 1,946) 
P. aeruginosa 
(n = 77) P Value 
    Invasive 111 (6.5) 6 (10.3) 0.25 
Severe CAP, No (%) 410 (27.8) 31 (60.8) <0.001 
Length of hospital stay (days), median (1st 
quartile; 3rd quartile) 
7.0 (5.0; 12.0) 13.0 (7.0; 16.5) <0.001 
30-day mortality, No. (%) 107 (5.5) 14 (18.2) <0.001 
Appropriate empiric treatment, No. (%) 1,393 (89.9) 28 (36.4) <0.001 
Abbreviations: CAP indicates community acquired pneumonia; COPD, chronic obstructive respiratory 
disease; CURB-65, consciousness, urea, respiratory rate, blood pressure, 65; ICU, intensive care unit; PSI, 
pneumonia severity index. 
Percentages calculated on non-missing data. 
*May have more than 1 comorbid condition. 
#
Optimal cut-off value using ROC curves. 
$
Patients who received initially non-invasive ventilation but needed subsequently intubation were 
included in the invasive mechanical ventilation group. 
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Table 2. Clinical and Epidemiological Characteristics of MDR and non-MDR P. 
aeruginosa CAP 
 
MDR P. 
aeruginosa 
(n = 22) 
Non-MDR P. 
aeruginosa 
(n = 46) P Value 
Demographic    
    Age (years), mean (SD) 72.7 (15.6) 71.1 (13.6) 0.45 
    Male gender, No. (%) 20 (90.9) 36 (78.3) 0.20 
    Current smoker, No. (%) 3 (14.3) 11 (25.6) 0.31 
    Current alcohol consumer, No. (%) 5 (23.8) 11 (25.6) 0.88 
Previous antibiotic, No. (%) 11 (57.9) 12 (28.6) 0.029 
Influenza vaccine, No. (%) 9 (52.9) 14 (43.8) 0.54 
Pneumococcal vaccine, No. (%) 3 (17.6) 8 (25.0) 0.56 
Inhaled corticosteroid, No. (%) 12 (57.1) 19 (43.2) 0.29 
Systemic corticosteroid, No. (%) 0 3 (8.6) 0.20 
Comorbidities, No. (%)* 20 (90.9) 37 (80.4) 0.27 
    Chronic respiratory disease 17 (77.3) 28 (63.6) 0.26 
        Chronic bronchitis 1 (4.5) 2 (4.5) >0.99 
        Bronchiectasis 0 4 (9.1) 0.29 
        COPD 9 (40.9) 18 (40.9) >0.99 
        Asthma 1 (4.5) 1 (2.3) >0.99 
    Chronic cardiovascular disease 6 (27.3) 7 (15.9) 0.27 
    Diabetes mellitus 4 (19.0) 10 (22.2) 0.77 
    Neurological disease 4 (19.0) 7 (16.3) 0.78 
    Chronic renal disease 3 (13.6) 3 (6.8) 0.36 
    Chronic liver disease 2 (9.1) 3 (6.7) 0.72 
Previous episode of pneumonia, No. (%) 10 (45.5) 9 (20.5) 0.034 
Nursing-home, No. (%) 2 (9.1) 2 (4.5) 0.47 
CURB-65 risk class 3-5, No. (%) 8 (38.1) 13 (30.2) 0.53 
PSI risk class IV-V, No. (%) 17 (77.3) 31 (70.5) 0.56 
ICU admission, No. (%) 6 (27.3) 11 (23.9) 0.77 
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MDR P. 
aeruginosa 
(n = 22) 
Non-MDR P. 
aeruginosa 
(n = 46) P Value 
Mechanical ventilation, No. (%)#   0.69 
    Not ventilated 11 (84.6) 32 (88.9) 0.69 
    Non-invasive 0 0 - 
    Invasive 2 (15.4) 4 (11.1) 0.69 
Severe CAP, No. 9 (75.0) 18 (58.1) 0.30 
Length of hospital stay (days), median 
(1st quartile; 3rd quartile) 
14.0 (12.0; 21.0) 11.0 (7.0; 16.0) 0.046 
30-day mortality, No. (%) 5 (22.7) 8 (17.4) 0.60 
Appropriate empiric treatment, No. (%) 5 (22.7) 18 (39.1) 0.18 
Abbreviations: MDR indicates multidrug resistant; CAP, community acquired pneumonia; COPD, chronic 
obstructive respiratory disease; CURB-65, consciousness, urea, respiratory rate, blood pressure, 65; ICU, 
intensive care unit; PSI, pneumonia severity index. 
Percentages calculated on non-missing data. 
*May have more than 1 comorbid condition. 
#
Patients who received initially non-invasive ventilation but needed subsequently intubation were 
included in the invasive mechanical ventilation group. 
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Table 3. Significant Univariate and Multivariate Logistic Regression Analyses of 
Associations of CAP Due to P. aeruginosa   
 
Abbreviations: CI indicates confidence interval; OR, odds ratio; PSI, pneumonia severity index. 
*Hosmer-Lemeshow goodness-of-fit test, p=0.57. 
#
Optimal cut-off value to predict P. aeruginosa using ROC curves. 
Variable 
Univariate Multivariate* 
OR 95% CI P Value OR 95% CI P Value 
Age ≥65 years 2.61 1.49-4.56 0.001 - - - 
Male gender 3.42 1.84-6.38 <0.001 3.71 1.65-8.35 0.002 
Current smoker 1.45 0.72-2.93 0.30 - - - 
Inhaled corticosteroids 3.47 2.16-5.56 <0.001 - - - 
Prior antibiotic treatment 1.90 1.15-3.15 0.013 - - - 
Previous episode of pneumonia 2.33 1.39-3.92 0.001 - - - 
Chronic respiratory disease 2.78 1.70-4.56 <0.001 2.26 1.25-4.10 0.007 
C-reactive protein <12.35 mg/dL# 1.99 1.18-3.36 0.010 1.91 1.08-3.38 0.027 
PSI risk class IV-V 2.52 1.51-4.21 <0.001 1.85 1.00-3.41 0.049 
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Table 4. Significant Univariate and Multivariate Logistic Regression Analyses of 
Associations of CAP Due to MDR P. aeruginosa 
 
 
Abbreviations: MDR indicates multidrug resistant CI, confidence interval; OR, odds ratio. 
*Hosmer-Lemeshow goodness-of-fit test, not applicable. 
Variable 
Univariate Multivariate* 
OR 95% CI P Value OR 95% CI P Value 
Prior antibiotic treatment 3.44 1.11-10.64 0.032 3.32 1.07-10.31 0.038 
Previous episode of pneumonia 3.24 1.06-9.87 0.039 - - - 
White blood cell count <10 × 109/L 3.66 1.13-11.82 0.030 - - - 
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Table 5. Significant Univariate and Multivariate Logistic Regression Analyses of 
Predictors of 30-Day Mortality 
Abbreviations: CI indicates confidence interval; ICU, intensive care unit; OR, odds ratio; PSI, pneumonia 
severity index. 
*Hosmer-Lemeshow goodness-of-fit test, p=0.064. 
#
The p-value corresponds to differences between the three groups (not ventilated, non-invasive or 
invasive). 
 
Variable 
Univariate Multivariate* 
OR 95% CI P Value OR 95% CI P Value 
CAP due to P. aeruginosa 3.78 2.05-6.97 <0.001 2.39 1.02-5.59 0.045 
Age ≥65 years 4.15 2.49-6.90 <0.001 2.62 1.32-5.19 0.006 
Current smoker 0.50 030-0.82 0.006 - - - 
Inhaled corticosteroids 1.47 0.96-2.25 0.077 - - - 
Chronic cardiovascular disease 2.12 1.36-3.31 0.001 - - - 
Chronic renal disease 2.01 1.09-3.69 0.024 - - - 
Chronic liver disease 2.50 1.35-4.63 0.003 4.17 1.89-9.21 <0.001 
Neurological disease 3.47 2.32-5.20 <0.001 3.68 2.05-6.64 <0.001 
Nursing home 3.67 2.13-6.34 <0.001 3.69 1.51-8.99 0.004 
PSI risk class IV-V 6.75 3.96-11.52 <0.001 - - - 
Creatinine ≥1.5 mg/dL 4.64 3.17-6.79 <0.001 - - - 
Multilobar infiltration 1.93 1.32-2.84 0.001 - - - 
Acute respiratory distress syndrome 4.68 2.56-8.56 <0.001 - - - 
Acute renal failure 5.57 3.76-8.27 <0.001 4.22 2.48-7.20 <0.001 
Septic shock 6.46 4.19-9.97 <0.001 - - - 
ICU admission 3.54 2.43-5.17 <0.001 5.27 3.05-9.12 <0.001 
Mechanical ventilation#   <0.001   - 
    Not ventilated 1 - - - - - 
    Non-invasive 5.67 2.64-12.22 <0.001 - - - 
    Invasive 19.09 11.63-31.32 <0.001 - - - 
Appropriate empiric treatment 0.29 0.18-0.46 <0.001 0.40 0.22-0.76 0.005 
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